可操作遗传筛选揭示AURKA、MEK与脂肪酸代谢联合靶向治疗晚期黑色素瘤
本研究在转移性黑色素瘤患者来源异种移植瘤中建立离体功能遗传筛选,发现alisertib与trametinib双靶向AURKA和MEK高效,且优于标准治疗;联合脂肪酸氧化抑制剂etomoxir三药方案进一步诱导肿瘤消退并显著延长小鼠总生存。
要点
- 离体遗传筛选可分离预测药物疗效的可操作脆弱性。
- alisertib联合trametinib在BRAF突变及靶向耐药模型均优于标准治疗。
- alisertib联合trametinib上调脂肪酸氧化通路,加etomoxir三药进一步获益。
核心结论
- alisertib与trametinib联合靶向AURKA和MEK在转移性黑色素瘤患者来源异种移植瘤中高效,且优于标准治疗。
- alisertib与trametinib治疗上调脂肪酸氧化通路,联合etomoxir三药方案进一步诱导肿瘤消退并显著延长小鼠总生存。
研究设计与样本
- 在转移性黑色素瘤患者来源异种移植瘤上建立基于drop-out遗传筛选的离体临床前功能检测。
- 在离体和在体条件下评估alisertib与trametinib联合,并在BRAF突变及靶向治疗耐药模型中与标准治疗比较。
主要发现
- alisertib与trametinib联合在离体和在体条件下对一组转移性黑色素瘤患者来源异种移植瘤高度有效。
- alisertib与trametinib联合在BRAF突变患者来源异种移植瘤和靶向治疗耐药模型中均优于标准治疗。
- alisertib与trametinib治疗引起早期代谢重编程,导致脂肪酸氧化通路转录上调。
- alisertib、trametinib与脂肪酸氧化抑制剂etomoxir三药联合进一步获益,诱导肿瘤消退并显著延长小鼠总生存。
关键数值与推荐
- alisertib与trametinib双靶向AURKA和MAPK/细胞外信号调节激酶激酶在患者来源异种移植瘤中高效。
- alisertib与trametinib联合在BRAF突变和靶向治疗耐药模型中均优于标准治疗。
- alisertib与trametinib治疗上调脂肪酸氧化通路,三药联合加etomoxir进一步诱导肿瘤消退并延长小鼠总生存。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the remarkable improvements achieved in the management of metastatic melanoma, there are still unmet clinical needs. A considerable fraction of patients does not respond to immune and/or targeted therapies owing to primary and acquired resistance, high-grade immune-related adverse events, and a lack of alternative treatment options. To design effective combination therapies, we set up a functional ex vivo preclinical assay on the basis of a drop-out genetic screen in metastatic melanoma patient-derived xenografts. We showed that this approach can be used to isolate actionable vulnerabilities predictive of drug efficacy. In particular, we highlighted that the dual targeting of AURKA and MAPK/extracellular signal-regulated kinase kinase employing the combination of alisertib and trametinib is highly effective in a cohort of metastatic melanoma patient-derived xenografts, both ex vivo and in vivo. Alisertib and trametinib combination therapy outperforms standard-of-care therapy in both BRAF-mutant patient-derived xenografts and targeted therapy-resistant models. Furthermore, alisertib and trametinib treatment modulates several critical cancer pathways, including an early metabolic reprogramming that leads to the transcriptional upregulation of the fatty acid oxidation pathway. This acquired trait unveiled an additional point of intervention for pharmacological targeting, and indeed, the triple combination of alisertib and trametinib with the fatty acid oxidation inhibitor etomoxir proved to be further beneficial, inducing tumor regression and remarkably prolonging the overall survival of the mice.
引用
- Marocchi F, Palluzzi F, Nicoli P, et al. Actionable Genetic Screens Unveil Targeting of AURKA, MEK, and Fatty Acid Metabolism as an Alternative Therapeutic Approach for Advanced Melanoma. J Invest Dermatol. 2023. PMID: 37003468. doi:10.1016/j.jid.2023.03.1665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。